Topical Eye Composition for Intraocular Vascular Leakage

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for intraocular vascular leakage, such as laser therapy and invasive surgery, are inconvenient and require frequent administration, causing pain and side effects, while existing drugs for intraocular diseases need repetitive administration every 4-6 weeks.

Innovation Solution

A pharmaceutical composition containing (7S)-(+)-cyclopentylcarbarmic acid, 8,8-dimethyl-2-oxo-6,7-dihydro-2H,8H-pyrano[3,2-g]chromen-7-yl-ester is developed for topical administration, which effectively inhibits intraocular vascular leakage, reducing the frequency of administration and minimizing side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If laser treatment is used to prevent vascular leakage, then therapeutic effect is improved, but patient convenience deteriorates due to invasive procedure and pain

Engineering Contradiction:

Improvetherapeutic effectVSAvoidpatient convenience

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces the mechanical laser treatment system with a chemical pharmaceutical composition (compound 1) that can be administered topically to the eye. This substitution eliminates the need for invasive laser procedures while maintaining therapeutic effectiveness in treating vascular leakage in eye diseases.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If existing drugs are administered directly into the vitreous cavity, then therapeutic effect is improved, but medication frequency increases requiring administration every 4-6 weeks

Engineering Contradiction:

Improvetherapeutic effectVSAvoidmedication frequency

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent changes the administration route parameter from intravitreal injection to topical eye administration, and uses compound 1 which provides sustained therapeutic effect. This allows less frequent dosing while maintaining effective treatment of vascular leakage.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If existing drugs are administered directly into the vitreous cavity, then therapeutic effect is improved, but side effects increase causing inconvenience and pain

Engineering Contradiction:

Improvetherapeutic effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the invasive intravitreal injection method with a non-invasive topical administration approach using compound 1. This substitution eliminates procedural pain and reduces side effects associated with direct vitreous cavity injection while preserving therapeutic effectiveness.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

4Reliability

If invasive surgery is performed for intraocular diseases, then therapeutic effect is improved, but patient convenience deteriorates due to surgical recovery and discomfort

Engineering Contradiction:

Improvetherapeutic effectVSAvoidpatient convenience

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces invasive surgical interventions with a pharmacological treatment using compound 1 administered as eye drops or ointment. This substitution eliminates surgical recovery time and discomfort while providing effective treatment for intraocular vascular leakage.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS12558339B2Composition comprising (7S)-(+)-cyclopentyl carbarmic acid, 8,8-dimethyl-2-oxo-6,7-dihydro-2H,8H-pyrano[3,2-g]chromen-7-yl-ester as active ingredient for prevention, alleviation, or treatment of eye disease

Publication Date: 2026.02.24 INSPHARMTECH INC

AI summary

The present disclosure relates to a composition for preventing, alleviating or treating an eye disease, which contains (7S)-(+)-cyclopentylcarbarmic acid, 8,8-dimethyl-2-oxo-6,7-dihydro-2H,8H-pyrano[3,2-g]chromen-7-yl-ester as an active ingredient. The (7S)-(+)-cyclopentylcarbarmic acid, 8,8-dimethyl-2-oxo-6,7-dihydro-2H,8H-pyrano[3,2-g]chromen-7-yl-ester of the present disclosure exhibits the effect of remarkably reducing intraocular vascular leakage and, as such, can be advantageously used in a composition for preventing, alleviating or treating an eye disease.